#United States #Phoenix #Celltrion #OMLYCLO #CT-P39

Introduction

Celltrion recently announced that it will present compelling findings about its innovative treatment OMLYCLO® (omalizumab-igec), during the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting. The studies focus on the treatment's effectiveness in chronic spontaneous urticaria (CSU), a condition often debilitating for those affected.

Efficacy of OMLYCLO®

During the ACAAI event on November 14 and 15, three post hoc analyses from a Phase 3 trial of OMLYCLO will be put under the spotlight. These analyses provide an in-depth look into how the treatment has not only improved the quality of life for CSU patients but has also demonstrated comparable efficacy to the reference drug omalizumab. A central finding shows that patients reported quality-of-life improvements that outpaced disease control responses.

Specifically, the data shows that 41.7% of patients maintained both disease control and an enhanced quality of life for up to 16 weeks following the cessation of treatment. Such findings highlight not only the immediate benefits of OMLYCLO but also its potential for lasting positive effects.

Analysis Focus Areas

One of the notable analyses presented will explore the intricacies between disease activity and quality of life during treatment with omalizumab. It aims to understand how patients perceive and report their quality of life in correlation with their disease severity throughout the treatment duration.

Another analysis looks into the efficacy of OMLYCLO based on baseline itch severity, examining how different patient profiles respond to treatment over time. This part of the research reveals that no matter the initial severity of their condition, patients experienced significant reductions in their Dermatology Life Quality Index scores, indicating consistent improvement across diverse groups.

Additionally, the pharmacokinetics of OMLYCLO in patients who also have asthma will be explored in a subgroup analysis. This will illustrate how well the drug interacts with the body’s system compared to the reference product, giving insights into tailored treatment approaches for patients burdened with multiple conditions.

Importance of Research Findings

Dr. Juby Jacob-Nara, Senior Vice President and Chief Medical Officer at Celltrion USA, emphasized the comprehensive nature of the analyses presented, declaring that chronic spontaneous urticaria can significantly affect not just skin conditions but also patients' overall well-being. The research underlines the importance of integrating quality-of-life measures into clinical outcomes for conditions like CSU, which exhibit systemic effects and comorbidities.

Conclusion

This data marks a considerable advancement in understanding chronic spontaneous urticaria and positions OMLYCLO as a noteworthy option for treatment, not just another pharmacological solution. As the only FDA-approved interchangeable biosimilar to XOLAIR®, OMLYCLO has shown both in research and clinical application that it can deliver on the promise of alleviating symptoms when traditional treatments fall short. Moving forward, ongoing studies will likely continue to dissect the multifaceted impact of CSU on patients' lives, potentially leading to even more refined treatment paths.

Ultimately, it reinforces Celltrion's dedication to pioneering research and development in allergy and immunology, striving to improve patient outcomes with innovative solutions in the biopharmaceutical landscape.

For more updates on the studies presented at ACAAI 2026 and OMLYCLO's ongoing journey, follow Celltrion on their various social media platforms and their website.